Structure of the murine fifth complement component (C5) gene. A large, highly interrupted gene with a variant donor splice site and organizational homology with the third and fourth complement component genes

Haviland, David L.; Haviland, Joie C.; Fleischer, Daniel T.; Wetsel, Rick A.

doi:10.1016/s0021-9258(18)99030-7

Cited by 36 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genomic Southern Analysis. Genomic Southern analysis was conducted as described (Haviland et al, 1991). Ten micrograms of either U937 or HL-60 high molecular weight DNA was digested overnight with the restriction endonucleases described in Figure 2A.…”

mentioning

confidence: 99%

Structure, 5'-flanking sequence, and chromosome location of the human N-formyl peptide receptor gene. A single-copy gene comprised of two exons on chromosome 19q.13.3 that yields two distinct transcripts by alternative polyadenylation

et al. 1993

View full text Add to dashboard Cite

The N-formyl peptide chemoattractant receptor (fMLF-R) is a cell-surface, G-protein-coupled glycoprotein that mediates the directed locomotion of neutrophils upon binding N-formylated peptides. The fMLF-R is encoded primarily by a 1.6-kb mRNA in differentiated HL-60 and U937 cells, although larger less abundant transcripts are present. To study the origin of different fMLF-R transcripts, the genetic linkage of chemotactic receptor genes, and the regulation of fMLF-R gene expression, we determined the copy number, chromosomal location, structural organization, and 5'-flanking sequence of the human fMLF-R gene. BamHI restriction fragments derived from a human fMLF-R genomic cosmid clone were isolated, subcloned, and sequenced. These data indicate that the fMLF-R structural gene is approximately 7.5 kb in length and is comprised of two exons separated by an approximately 5.0-kb intron. The first exon encodes 66 bp of the 5'-untranslated sequence, while exon 2 encodes the coding and 3'-untranslated sequences. The genomic organization of the fMLF-R gene is similar to that of the adrenergic beta-1 and beta-2 G-protein-coupled receptor genes in that the coding sequence is contained in a single exon. The different 3'-untranslated sequences observed in fMLF-R cDNA clones are contiguous in the genomic structure, thereby indicating that these clones are derived in part by alternative polyadenylation. Southern blot analysis using human X hamster somatic cell hybrids and in situ hybridization indicated that the h-fMLF-R gene is located on chromosome 19q13.3. Primer extension experiments using dbcAMP-differentiated U937 RNA indicated a single transcriptional initiation site. Sequence analysis 5' of the transcriptional initiation site indicated possible cis-acting motifs that may regulate fMLF-R gene expression. These included AP-1 and CK-2 consensus sequences that bind nuclear factors of the Fos/Jun family and NF-GMb, respectively.

show abstract

mentioning

confidence: 99%

Structure, 5'-flanking sequence, and chromosome location of the human N-formyl peptide receptor gene. A single-copy gene comprised of two exons on chromosome 19q.13.3 that yields two distinct transcripts by alternative polyadenylation

et al. 1993

View full text Add to dashboard Cite

show abstract

“…Because (1) autoantigens are generally immune tolerized, (2) previous studies suggest that conservative antigens from different species could elicit the production of antibodies that cross-react with the autoantigens, − and (3) mouse and human C5 protein share >80% homology, we initially immunized mice with purified human C5 protein, hoping that the developed polyclonal antibodies could cross-react with mouse C5, therefore inhibiting mouse C5 activity in vivo . Indeed, mice immunized with human C5 protein developed high titers of antibodies against human C5 (Figure A); however, sera from these immunized mice had similar potency as sera from control mice in lysing sensitized sheep erythrocytes ex vivo (Figure B).…”

Section: Resultsmentioning

confidence: 99%

Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo

et al. 2017

View full text Add to dashboard Cite

The complement system is emerging as a new target for treating many diseases. For example, Eculizumab, a humanized monoclonal antibody against complement component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) in which patient erythrocytes are lysed by complement. In this study, we developed vaccines to elicit autologous anti-C5 antibody production in mice for complement inhibition. Immunization of mice with a conservative C5 xenoprotein raised high titers of IgGs against the xenogenous C5, but these antibodies did not reduce C5 activity in the blood. In contrast, an autologous mouse C5 vaccine containing multiple predicted epitopes together with a tolerance-breaking peptide was found to induce anti-C5 autoantibody production in vivo, resulting decreased hemolytic activity in the blood. We further validated a peptide epitope within this C5 vaccine and created recombinant virus-like particles (VLPs) displaying this epitope fused with the tolerance breaking peptide. Immunizing mice with these novel nanoparticles elicited strong humoral responses against recombinant mouse C5, reduced hemolytic activity, and protected the mice from complement-mediated intravascular hemolysis in a model of PNH. This proof-of-concept study demonstrated that autologous C5-based vaccines could be an effective alternative or supplement for treating complement-mediated diseases such as PNH.

show abstract

Localization of self antigen: implications for antigen presentation and induction of tolerance

Stockinger

Cf²,

Hausmann³

1993

Eur J Immunol

View full text Add to dashboard Cite

The fifth component of complement (C5) is a self antigen expressed in serum of normal mice at a concentration of about 50 micrograms/ml. We have previously shown that C5 is constitutively processed and presented by antigen-presenting cells (APC) in normal mice to induce and maintain complete tolerance in major histocompatibility complex (MHC) class II-restricted T cells. This report addresses the question of whether C5 presentation involves exogenous antigen which has been internalized for processing or whether intracellular, biosynthesized C5 is being presented with MHC class II. Macrophages were found to synthesize, but not secrete C5 in bone marrow chimeras made from irradiated C5-deficient [C5(-)] hosts reconstituted with C5-sufficient [C5(+)] bone marrow [C5(+)-->C5(-)]. In these mice, macrophages are the only source of C5. [C5(+)-->C5(-)] chimeras are not tolerant of C5 and generate C5-specific T and B cell responses upon immunization indistinguishable from those of C5(-) mice. Macrophages from [C5(+)-->C5(-)] chimeras are unable to activate C5-specific T cell hybrids in vitro unlike macrophages from a C5(-) strain that has matured in a C5-expressing environment [C5(-)-->C5(+) chimeras]. This shows that under physiological conditions in vivo intracellular C5 does not get access to the class II presentation pathway and thus, does not induce tolerance in class II-restricted T cells.

show abstract

Structure of the murine fifth complement component (C5) gene. A large, highly interrupted gene with a variant donor splice site and organizational homology with the third and fourth complement component genes

Cited by 36 publications

References 34 publications

Structure, 5'-flanking sequence, and chromosome location of the human N-formyl peptide receptor gene. A single-copy gene comprised of two exons on chromosome 19q.13.3 that yields two distinct transcripts by alternative polyadenylation

Structure, 5'-flanking sequence, and chromosome location of the human N-formyl peptide receptor gene. A single-copy gene comprised of two exons on chromosome 19q.13.3 that yields two distinct transcripts by alternative polyadenylation

Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo

Localization of self antigen: implications for antigen presentation and induction of tolerance

Contact Info

Product

Resources

About